Last updated: August 20, 2026
[Key Takeaways]
- On August 5, 2026, the FDA approved mFlusiva (mRNA-1010), the first mRNA-based vaccine for seasonal influenza.
- The vaccine is indicated for adults 50 and older, but the approval pathway differs by age: traditional approval for ages 50-64, and accelerated approval for adults 65 and older.
- The accelerated approval for adults 65+ is based on immunogenicity data, and a confirmatory trial to verify clinical benefit is ongoing.
- In a Phase 3 trial of more than 40,000 adults 50 and older, mFlusiva showed roughly 26.6% greater relative efficacy compared with a standard-dose flu vaccine.
- Older adults remain at elevated risk for severe flu-related outcomes, and the 2026-27 respiratory season's optimal vaccination window is typically September through October.
It is written in the hope that it can be of even a little help to many readers.
Overview
On August 5, 2026, the U.S. Food and Drug Administration approved mFlusiva (mRNA-1010), Moderna's mRNA-based seasonal influenza vaccine, marking the first time an mRNA platform has been cleared for use against the flu. The approval covers adults 50 and older, but it comes with an important nuance: the regulatory pathway differs depending on age. Adults ages 50-64 received the vaccine under a traditional, full approval, while adults 65 and older were granted access through an accelerated approval — a designation that carries specific meaning about what evidence exists and what is still being confirmed. This article walks through what mFlusiva is, who qualifies for it, how it performed in clinical trials, why flu protection carries added weight for older adults, and what to know before deciding whether it is the right choice for the upcoming respiratory season.
Table of Contents
What Is the New mRNA Flu Vaccine?
mFlusiva (mRNA-1010) is the vaccine manufacturer Moderna developed using the same messenger RNA technology behind its COVID-19 vaccine, applied for the first time to seasonal influenza. The FDA's August 5, 2026 approval represents the first authorization of an mRNA-based vaccine for flu in the United States.[1] Instead of using an inactivated virus or a lab-grown viral protein, as conventional flu vaccines do, mFlusiva delivers genetic instructions that prompt the body's own cells to produce a flu virus protein, which then trains the immune system to recognize the actual virus.
[1] Moderna, "FDA Approval for Influenza Vaccine mFLUSIVA" (press release) (2026)
How mRNA Flu Vaccines Differ From Traditional Shots
Most flu vaccines available in past seasons are manufactured either by growing virus in chicken eggs or cell cultures, or by using recombinant protein technology. Manufacturing timelines for those methods generally require selecting a viral strain composition many months before flu season begins. mRNA vaccine manufacturing is generally faster and more flexible to adapt, which is one reason developers have pursued this platform for respiratory viruses. Formulation strategy aside, the intended outcome is the same across platforms: prompting the immune system to develop a response that may help reduce the risk of infection or severe illness from circulating flu strains.
Who Can Get It: The 50+ Indication Explained
The FDA's approval of mFlusiva applies to adults age 50 and older, but the two age groups within that range were evaluated and approved under different regulatory standards. Adults ages 50-64 qualify under a traditional approval, while adults 65 and older qualify under an accelerated approval — a distinction that affects how much confirmed clinical evidence currently backs the vaccine's benefit in each group.
| Category | Ages 50-64 | Ages 65 and Older |
|---|---|---|
| Approval Type | Traditional (standard) approval | Accelerated approval |
| Evidence Basis | Demonstrated clinical efficacy | Immunogenicity data |
| Confirmatory Trial Status | Not applicable | Ongoing |
What "Accelerated Approval" Means for Adults 65+
Accelerated approval is a distinct FDA pathway used when a product shows a reasonably likely benefit through a measurable marker — in this case, immunogenicity, meaning the strength of the immune response the vaccine generates in blood samples — rather than confirmed clinical outcomes like fewer flu cases or hospitalizations. For adults 65 and older, mFlusiva's approval rests on immunogenicity data showing an adequate immune response, and a confirmatory trial designed to verify actual clinical benefit in this age group is still underway.[1] This is not unique to vaccines; the accelerated pathway has long been used for other products, with the expectation that additional evidence follows. In practical terms, it means the vaccine is authorized for use in this population based on a reasonable scientific expectation of benefit, while direct evidence of reduced flu illness or complications in adults 65+ specifically is still being gathered.
[1] FDA, MFLUSIVA Approval & Prescribing Information (2026)
How Well Does It Work?
Moderna's Phase 3 trial enrolled more than 40,000 adults age 50 and older to compare mFlusiva against a standard-dose flu vaccine. The trial found mFlusiva was associated with approximately 26.6% greater relative efficacy compared with a standard-dose vaccine in preventing symptomatic, laboratory-confirmed influenza.[1] A relative efficacy figure like this describes how mFlusiva performed compared with an existing vaccine within the trial population, not an absolute guarantee of protection for any individual. As with any flu vaccine, effectiveness can vary from season to season depending on how closely circulating strains match the strains included in that year's formulation.
[1] Leroux-Roels et al., N Engl J Med (FLUENT trial) (2026)
Why Flu Protection Matters More After 65
Age-related changes in immune function generally make older adults more susceptible to severe complications from respiratory infections, including influenza. Adults 65 and older account for a disproportionate share of flu-related hospitalizations and deaths in the United States each season.[1] This elevated risk is one reason public health guidance has long emphasized annual flu vaccination for this age group, and it is also the backdrop against which a new vaccine platform, and its accelerated approval pathway for adults 65+, is being evaluated. Underlying chronic conditions common among older adults, such as heart disease, diabetes, and chronic lung disease, can further compound flu-related risk.
[1] CDC, "Flu & People 65 Years and Older" (2026); Systematic review, PMC9930064 (2023)
Timing: When to Get Vaccinated for 2026-27
As the 2026-27 respiratory virus season approaches, timing remains an important consideration regardless of which flu vaccine an individual chooses. Public health guidance has generally recommended getting a flu vaccine by the end of October, with September and October considered the optimal window for most adults.[1] Getting vaccinated too early in the summer may mean reduced protection later in the season, as vaccine-induced immunity can wane over several months, while waiting too long risks missing protection before flu activity typically rises in late fall and winter. Availability of mFlusiva at individual pharmacies and clinics may vary in the weeks following FDA approval, so adults interested in the mRNA option may want to confirm availability with their pharmacy or healthcare provider ahead of their planned vaccination date.
[1] CDC, "2026-2027 Flu Season" (2026)
What Older Adults Should Consider Before Deciding
Choosing between mFlusiva and a conventional flu vaccine, such as a high-dose or adjuvanted formulation already recommended for older adults, is a decision best made with a healthcare provider who knows an individual's full medical history. A few factors may be worth discussing:
Understand the evidence gap for your age group. Adults 65 and older should be aware that mFlusiva's approval in this age bracket relies on immunogenicity data while confirmatory clinical trials continue, which differs from the fuller efficacy evidence base behind some established flu vaccines for this population.
Ask about existing options for adults 65+. High-dose and adjuvanted flu vaccines have an established track record in older adults and remain available this season; a healthcare provider can help weigh the relative evidence behind each option.
Consider individual health history. People with a history of severe allergic reaction to a previous flu vaccine, or with other relevant medical conditions, should talk to their healthcare provider about which vaccine formulation may be appropriate.
Factor in personal risk level. Adults with chronic conditions or compromised immune function may want to discuss timing and vaccine choice with their provider in more detail, since their individual risk profile may inform the decision.
None of these considerations suggest that one option is unsafe or ineffective; rather, they reflect that adults now have more than one evidence-based path to flu protection, each with a different regulatory and research history behind it.
Common Questions About the mRNA Flu Vaccine
Is mFlusiva the same technology as the COVID-19 mRNA vaccines?
The underlying mRNA platform is similar in concept, using genetic instructions to prompt the body to produce a viral protein that trains the immune system. However, mFlusiva is formulated specifically to target influenza virus proteins rather than the coronavirus spike protein, and it went through its own separate clinical development and FDA review process.
Can adults 65 and older choose a traditional flu vaccine instead of mFlusiva?
Yes. mFlusiva's approval adds a new option; it does not replace existing flu vaccines recommended for older adults, including high-dose and adjuvanted formulations that have a longer track record of clinical outcome data in this age group.
Does accelerated approval mean the vaccine is less safe?
Accelerated approval relates to the type of evidence supporting an expected benefit, not to the safety review process. mFlusiva underwent the same safety evaluation required for FDA approval; the accelerated pathway specifically concerns confirming clinical benefit for adults 65+ through immunogenicity data while a confirmatory trial for that age group continues.
Will mFlusiva be available everywhere this flu season?
Availability may vary by location and pharmacy in the initial rollout period following the August 5, 2026 approval. Adults interested in the vaccine may want to check with their local pharmacy, clinic, or healthcare provider about availability ahead of their planned vaccination visit.
References
- Moderna, Inc. "Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA." Press release, August 5, 2026. https://www.biospace.com/press-releases/moderna-receives-u-s-fda-approval-for-influenza-vaccine-mflusiva
- U.S. Food and Drug Administration. "MFLUSIVA — Approval and Prescribing Information." 2026. https://www.fda.gov/vaccines-blood-biologics/mflusiva
- Leroux-Roels I, Huang G, et al. "Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults." New England Journal of Medicine. 2026;394(18):1803-1813. https://doi.org/10.1056/NEJMoa2516491
- Centers for Disease Control and Prevention. "Flu and People 65 Years and Older." 2026. https://www.cdc.gov/flu/highrisk/65over.htm ; and "High Clinical Burden of Influenza Disease in Adults Aged ≥65 Years: A Systematic Literature Review." 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC9930064/
- Centers for Disease Control and Prevention. "2026-2027 Flu Season." 2026. https://www.cdc.gov/flu/season/2026-2027.html ; ACIP recommendations, MMWR. https://www.cdc.gov/mmwr/volumes/74/wr/mm7432a2.htm
Comments
Post a Comment